ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer Meeting Abstract
| Authors: | Marth, C.; Vulsteke, C.; Rubio, M. J. R.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S.; Lee, J.; Pignata, S. |
| Abstract Title: | ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer |
| Meeting Title: | 51st Annual Meeting of the Society of Gynecologic Oncology (SGO) |
| Journal Title: | Gynecologic Oncology |
| Volume: | 159 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Mar 28-31 |
| Meeting Location: | Toronto, Canada |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-10-01 |
| Start Page: | 221 |
| Language: | English |
| ACCESSION: | WOS:000579556200474 |
| DOI: | 10.1016/j.ygyno.2020.05.366 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 478 -- This meeting was cancelled due to COVID-19 -- Source: Wos |
